VBI Vaccines - VBIV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New VBI Vaccines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VBIV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VBIV

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for VBI Vaccines in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for VBIV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in VBI Vaccines. This rating has held steady since October 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform$100.00 ➝ $40.00
8/9/2022Raymond JamesLower TargetStrong-Buy$120.00 ➝ $100.00
3/8/2022Raymond JamesLower TargetStrong-Buy$180.00 ➝ $120.00
12/30/2021Jefferies Financial GroupInitiated CoverageBuy$140.00 ➝ $120.00
5/21/2021Raymond JamesInitiated CoverageBuy
2/25/2021Jefferies Financial GroupInitiated CoverageBuy$140.00
8/27/2020OppenheimerReiterated RatingBuy$160.00
8/26/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$160.00 ➝ $180.00
7/22/2020Raymond JamesBoost TargetOutperform$60.00 ➝ $160.00
6/29/2020BMO Capital MarketsReiterated RatingBuy$80.00
6/23/2020OppenheimerBoost TargetOutperform$100.00 ➝ $160.00
5/7/2020OppenheimerReiterated RatingBuy$100.00
(Data available from 12/7/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/10/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
VBI Vaccines logo
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.23
Low: $0.02
High: $0.79

52 Week Range

Now: N/A

Volume

29,900,200 shs

Average Volume

3,655,737 shs

Market Capitalization

$1.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of VBI Vaccines?

The following Wall Street sell-side analysts have issued reports on VBI Vaccines in the last year: StockNews.com.
View the latest analyst ratings for VBIV.

What is the current price target for VBI Vaccines?

0 Wall Street analysts have set twelve-month price targets for VBI Vaccines in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for VBI Vaccines in the next year.
View the latest price targets for VBIV.

What is the current consensus analyst rating for VBI Vaccines?

VBI Vaccines currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VBIV.

What other companies compete with VBI Vaccines?

How do I contact VBI Vaccines' investor relations team?

VBI Vaccines' physical mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company's listed phone number is (617) 830-3031 and its investor relations email address is [email protected]. The official website for VBI Vaccines is www.vbivaccines.com. Learn More about contacing VBI Vaccines investor relations.